AUS
NZ
UK
CA
USA
IND
Highlights:
-
Accolade reported a 10% increase in revenue for fiscal Q2 2025, reaching $106.4 million, with a notable 27% improvement in net loss to $23.9 million.
-
Non-GAAP Adjusted EBITDA loss narrowed significantly by 68% to $2.8 million, while Adjusted Gross Margin expanded to 47.3%.
-
The company aims for its first full year of Adjusted EBITDA profitability and positive cash flow, highlighting progress in addressing the Physician Gap through a physician-led advocacy model.
Accolade {NASDAQ:ACCD} has announced its financial results for the second quarter of fiscal 2025, which concluded on August 31, 2024. The company reported a 10% increase in revenue, amounting to $106.4 million, alongside a 27% improvement in net loss, which decreased to $23.9 million.
The results reflect a narrowing of the Non-GAAP Adjusted EBITDA loss, which declined by 68% to $2.8 million. Additionally, Accolade achieved an expansion in its Adjusted Gross Margin, reaching 47.3%.
CEO Rajeev Singh expressed optimism regarding the company's trajectory, stating that Accolade is on track to deliver its first full year of Adjusted EBITDA profitability and positive cash flow. He emphasized the firm's commitment to addressing the Physician Gap through a physician-led advocacy approach, which aims to enhance patient care and access to healthcare services. CFO Steve Barnes underscored Accolade's successful execution in achieving profitable growth, noting an improvement of over $20 million in the net cash position compared to convertible debt over the past year. This financial performance positions Accolade favorably as it continues to drive its strategic initiatives forward.
